A new analysis calls into question the use of imaging alone to determine the efficacy of ablative radiation therapy. 

Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8. 

Trial results thus far indicate the drug can significantly extend progression-free survival compared to current standard of care treatments.

By giving providers greater insight into a tumor’s molecular footprint, the method could also reduce the need for invasive biopsies.

New findings related to Vesical Imaging-Reporting and Data System scores and specific MRI findings could improve the management of bladder cancer.